Protara Therapeutics Inc (TARA)
NASDAQ
| 日付 | 保有者名 | 取引株数 | 金額レンジ ($) | 取引種別 | 価格レンジ ($) | 届出終了時の株数 | % 変化 |
|---|---|---|---|---|---|---|---|
| 2026-06-02 | Mr. William ConklingChief Commercial Officer | -6.01k | 26.07k | Sale to Issuer | 4.34 | 69.99k | -7.91% |
| 2026-04-08 | Dr. Jacqueline ZummoCo-Founder, Chief R&D Officer | -1.13k | 6.12k | Automatic Disposition | 5.40 | 94.83k | -1.18% |
| 2026-04-01 | Dr. Jacqueline ZummoCo-Founder, Chief R&D Officer | -22.60k | 118.87k | Automatic Disposition | 5.26 | 41.96k | -35.00% |
| 2026-01-26 | Dr. Jacqueline ZummoCo-Founder, Chief R&D Officer | -3.72k | 24.84k | Sale to Issuer | 6.67 | 64.56k | -5.45% |
| 2026-01-26 | Mr. Jesse SheffermanCo-founder, CEO, President & Director | -8.73k | 58.24k | Sale to Issuer | 6.67 | 871.83k | -0.99% |
| 2026-01-26 | Ms. Hannah FryVP, Principal Accounting Officer & Controller | -1.46k | 9.72k | Sale to Issuer | 6.67 | 24.22k | -5.67% |
| 2026-01-26 | Mr. Patrick FabbioCFO | -3.26k | 21.75k | Sale to Issuer | 6.67 | 13.12k | -19.91% |
| 2026-01-20 | Mr. Patrick FabbioCFO | -3.06k | 17.15k | Sale to Issuer | 5.60 | 8.54k | -26.39% |
| 2026-01-20 | Dr. Jacqueline ZummoCo-Founder, Chief R&D Officer | -6.58k | 36.84k | Sale to Issuer | 5.60 | 60.12k | -9.86% |
| 2026-01-20 | Ms. Hannah FryVP, Principal Accounting Officer & Controller | -2.13k | 11.94k | Sale to Issuer | 5.60 | 22.51k | -8.65% |
| 2026-01-20 | Mr. Jesse SheffermanCo-founder, CEO, President & Director | -16.32k | 91.40k | Sale to Issuer | 5.60 | 858.90k | -1.86% |
| 2025-06-24 | Mr. Jesse SheffermanCo-founder, CEO, President & Director | -300.00k | 0.00 | Other Disposition | - | 838.45k | -26.35% |
| 2025-06-26 | Mr. Jesse SheffermanCo-founder, CEO, President & Director | -18.67k | 0.00 | Other Disposition | - | 838.45k | -2.18% |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。